Reducing off target viral delivery in ovarian cancer gene therapy using a protease-activated AAV2 vector platform

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit et al. · International Journal of Cancer · 2014 · 29K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

Andrea Bild, Guang Yao, Jeffrey T. Chang et al. · Nature · 2005 · 2.1K citations

Medicine, Cancer Biology, Oncology +14

Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection

Carmela Zincarelli, Stephen Soltys, Giuseppe Rengo et al. · Molecular Therapy · 2008 · 1.5K citations · Full text

Life Sciences, Biology, Molecular Biology +15

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors

Sylvie Boutin, Virginie Monteilhet, P. Véron et al. · Human Gene Therapy · 2010 · 947 citations

Life Sciences, Immunology, Molecular Biology +15

FIGO staging classifications and clinical practice gudelines in the management of gynecologic cancers

International Journal of Gynecology & Obstetrics · 2000 · 897 citations

Medicine, Gynecology, Oncology +13